Estimating the world cancer burden: Globocan 2000

Authors


Describing the distribution of disease between different populations and over time has been a highly successful way of devising hypotheses about causation and for quantifying the potential for preventive activities.1 Statistical data are also essential components of disease surveillance programs. These play a critical role in the development and implementation of health policy, through identification of health problems, decisions on priorities for preventive and curative programs and evaluation of outcomes of programs of prevention, early detection/screening and treatment in relation to resource inputs.

Over the last 12 years, a series of estimates of the global burden of cancer have been published in the International Journal of Cancer.2–6 The methods have evolved and been refined, but basically they rely upon the best available data on cancer incidence and/or mortality at country level to build up the global picture. The results are more or less accurate for different countries, depending on the extent and accuracy of locally available data. This “data-based” approach is rather different from the modeling method used in other estimates.7–10 Essentially, these use sets of regression models, which predict cause-specific mortality rates of different populations from the corresponding all-cause mortality.11 The constants of the regression equations derive from datasets with different overall mortality rates (often including historic data from western countries). Cancer deaths are then subdivided into the different cancer types, according to the best available information on relative frequencies.

GLOBOCAN 2000 updates the previously published data-based global estimates of incidence, mortality and prevalence to the year 2000.12

SOURCES OF DATA

The data sources that have been used to build up the global estimates are as follows.

Incidence

Incidence, the number of new cases occurring, can be expressed as the annual number of cases (the volume of new patients presenting for treatment) or as a rate per 100,000 persons per year. Incidence data are produced by population-based cancer registries.13 Registries may cover national populations or, more often, certain regions. In developing countries in particular, coverage is often confined to the capital city and its environs. It was estimated that, in 1990, about 18% of the world population were covered by registries, 64% of developed countries and 5% of developing countries, although the situation is improving each year. The most recent volume of “Cancer Incidence in Five Continents” (CI5) contains comparable incidence information from 150 registries in 50 countries, primarily over the period 1988–1992.14

Survival statistics

Survival statistics are also produced by cancer registries by the follow-up of registered cancer cases. Population-based figures are published by registries in many developed countries, for example, the SEER program covering 10% of the U.S. population15 and the EUROCARE II project, including 17 countries of Europe.16 Survival data from populations of China, the Philippines, Thailand, India and Cuba have been published by Sankaranarayanan et al.17

Mortality

Mortality is the number of deaths occurring and the mortality rate the number of deaths per 100,000 persons per year. It is the product of incidence and fatality (the inverse of survival) of a given cancer. Mortality rates measure the average risk to the population of dying from a specific cancer, while fatality (1-survival) represents the probability that an individual with cancer will die from it. Mortality data are derived from vital registration systems, where the fact and “underlying” cause of death are certified, usually by a medical practitioner. Their great advantage is comprehensive coverage and availability. By 1990, about 42% of the world population was covered by vital registration systems producing mortality statistics on cancer. Not all are, however, of the same quality in all countries. National-level statistics are collated and made available by the World Health Organiztion (http://www-dep.iarc.fr/dataava/globocan/who.htm), although for some countries coverage of the population is manifestly incomplete (so that the so-called mortality rates produced are implausibly low) and in others, quality of cause of death information is poor.

Frequency data

Frequency data, e.g., case series from hospitals and pathology laboratories, provide an indication of the relative importance of different cancers in a country or region in the absence of a population-based registry and mortality statistics. There are problems in extrapolating the results to the general population, since such series are subject to various forms of selection bias. Such data are generally published locally or in journal articles, although a few compendia are available.18, 19

Prevalence

Prevalence is the proportion of a population that has the disease at a given point in time.20 For many diseases (e.g., hypertension, diabetes), prevalence usefully describes the number of individuals requiring care. For cancer, however, many persons diagnosed in the past have been “cured”—they no longer have an excess risk of death (although some residual disability may be present, for example, following a resective operation). A straightforward comparison of need for cancer services can be made using partial prevalence, cases diagnosed within 1, 3 and 5 years, to indicate the numbers of persons undergoing initial treatment (cases within 1 year of diagnosis), clinical follow-up (within 3 years) or not considered “cured” (before 5 years). Patients alive 5 years after diagnosis are usually considered cured since, for most cancers, the death rates of such patients are similar to those in the general population.

MATERIAL AND METHODS

The methods used to produce the estimates are summarised in several recent articles.5, 6, 21, 22 The “Help” option of GLOBOCAN 2000 lists the sources of data and methods used for each country.

Incidence rates

Depending on the availability of data, national incidence rates are estimated, in order of priority, from:

  • National incidence data from good-quality cancer registries.

  • National mortality data, with estimation of incidence using sets of regression models specific for site, sex and age, derived from local cancer registry data (incidence plus mortality).

  • Local (regional) incidence data from 1 or more regional cancer registries within a country. When there are several cancer registries in the country, their incidence rates must be combined into a common set of values by some weighted average.

  • Local mortality data from some sort of sample survey of deaths, converted to incidence using specific models.

  • Frequency data. For several developing countries, only data on the relative frequency of different cancers (by age and sex) are available. These are applied to an estimated “all sites” incidence rate, derived from existing cancer registry results, in 7 world regions (Eastern Africa, Middle Africa, Northern Africa, Southern Africa, Western Africa, Middle East and Other Oceania).

  • No data. The country-specific rates are those of the corresponding world area (calculated from the other countries for which estimates could be made). There are few large countries that fall into this category. Those with a population greater than 10 million were Morocco, Afghanistan, Nepal, Sri Lanka, Mozambique, Madagascar and Yemen.

Mortality rates

National mortality rates, with for some countries a correction factor applied to account for known and quantified underreporting of deaths. Rates for missing sites were computed using proportions from mortality files provided by cancer registries.

When no national mortality data are available, local (regional) mortality rates derived from the data of 1 or more cancer registries covering a part of a country (state, province, etc.) were used.

When mortality data were unavailable or known to be of poor quality, mortality was estimated from incidence, using country/region-specific survival (see prevalence data).

In the absence of any data, country-specific rates are calculated from the average of those of neighbouring countries in the same regions.

Prevalence

Estimates of partial prevalence in each country were derived by combining the annual number of new cases and the corresponding probability of survival by time. For example, 1-year prevalence at a fixed point in mid-2000 was estimated from the number of new cases in 2000 multiplied by the probability of surviving at least 6 months, and 3-year prevalence sums the numbers alive at 0.5, 1.5 and 2.5 years. Relative survival data were obtained from the sources cited above and converted to observed survival using “normal” mortality probability (derived from the corresponding life tables). The shape of the survival curve from 0 to 5 years postdiagnosis was assumed to follow a Weibull distribution.22

RESULTS

GLOBOCAN 2000 presents incidence, mortality and prevalence data for 5 broad age groups (0–14, 15–44, 45–54, 55–64 and 65 and over) and sex for all countries of the world for 24 different types of cancer. Since cancer data are collected and compiled sometime after the events to which they relate, the most recent statistics available are from periods from 3–10 years earlier. The actual number of cancer cases, deaths and prevalent cases are calculated by applying these rates to the estimated world population for 2000, obtained from the most recent projections prepared by the United Nations Population Division.23

On the CD-ROM are computer programs to analyse and present the cancer database. The database itself may be downloaded from the Internet (http://www-dep.iarc.fr/globocan/globocan.htm). This site contains the most recently available estimates of the incidence and mortality rates in different countries worldwide.

GLOBOCAN 2000 can present the statistics described at any level of geographical aggregation and in tabular or graphical format (maps, bar charts, age-specific curves and pie charts). Some examples of these graphical presentations are shown on the cover of this issue. Tabulations of numbers and rates may also be displayed and printed. Incorporation of population projections for 5-year intervals, from 2005 to 2050,23 allows GLOBOCAN 2000 to be used to prepare projections of future burden, assuming current rates of incidence and mortality, or incorporating age/sex-specific rates of change in the rates.

Table I shows the most basic summary data of all—the global numbers of cases, deaths and prevalent cancers (within 5 years of diagnosis) by cancer site in males, females and both sexes. There are an estimated 10.1 million new cases, 6.2 million deaths and 22.4 million persons living with cancer in the year 2000. No attempt has been made to estimate incidence or mortality of nonmelanoma skin cancer because of the difficulties of measurement and consequent lack of data. The total “All Cancer” therefore excludes such tumours. The 2000 estimate represents an increase of around 22% in incidence and mortality since our most recent comprehensive estimates (for 1990). Lung cancer is the main cancer in the world today, whether considered in terms of numbers of cases (1.2 million) or deaths (1.1 million), because of the high case fatality (ratio of mortality:incidence = 0.9). However, breast cancer, although it is the second most common cancer overall (1.05 million new cases) ranks much less highly (5th) as a cause of death because of the relatively favourable prognosis (ratio of mortality:incidence = 0.4). Colon plus rectum is third in importance in terms of new cases (945,000 cases, 492,000 deaths), and stomach cancer (876,000 cases, 647,000 deaths) fourth. In terms of prevalence, the most common cancers are breast (3.9 million breast cancer cases), colorectal cancers (2.4 million) and prostate (1.6 million). The ratio between prevalence and incidence is an indicator of prognosis. This explains why breast cancer appears as the most prevalent cancer in the world, despite there being fewer new cases than for lung cancer, for which the outlook is considerably poorer.

Table I. Incidence, Mortality and Prevalence of Cancer Worldwide, 20001
 IncidenceMortalityPrevalence (5-year)
MaleFemaleBothMaleFemaleBothMaleFemaleBoth
  • 1

    Numbers of cases and deaths (1,000s).

Oral cavity169.597.1266.780.847.1127.9451.1256.0707.1
Nasopharynx46.018.864.826.711.137.8121.749.8171.5
Other pharynx100.922.1123.064.014.778.7201.847.0248.8
Oesophagus279.0133.3412.3226.9110.6337.5280.2135.7415.9
Stomach558.5317.9876.3405.2241.4646.6901.7496.31,398.1
Colon/rectum498.8446.0944.7254.8237.6492.41,245.11,133.92,379.0
Liver398.4166.0564.3383.6165.0548.6189.378.8268.1
Pancreas115.7100.7216.4112.0101.5213.561.351.0112.3
Larynx142.219.2161.478.610.589.1403.954.2458.1
Lung901.7337.11,238.9810.4292.71,103.11,013.5380.91,394.4
Melanoma of skin65.267.4132.620.017.137.0255.3277.8533.1
Prostate543.00.0543.0204.30.0204.31,554.70.01,554.7
Testis49.30.049.38.70.08.7200.10.0200.1
Breast0.01,050.31,050.30.0373.0373.00.03,860.33,860.3
Cervix uteri0.0470.6470.60.0233.4233.40.01,401.41,401.4
Corpus uteri0.0189.0189.00.044.744.70.0716.4716.4
Ovary, etc.0.0192.4192.40.0114.2114.20.0507.5507.5
Bladder259.876.0335.899.133.4132.4778.8220.9999.7
Kidney, etc.118.370.8189.156.734.491.1296.9183.1480.0
Brain, nervous system100.475.6176.171.656.0127.6169.0126.0295.0
Thyroid33.589.3122.88.617.426.0125.7349.4475.2
Non-Hodgkin lymphoma166.6120.8287.493.367.8161.1381.4291.2672.6
Hodgkin's disease38.223.962.215.79.224.9113.583.3196.8
Multiple myeloma39.534.573.930.427.057.474.369.3143.6
Leukaemia144.3112.8257.1109.385.9195.2233.1187.5420.6
All sites (excluding skin)5,317.94,737.610,055.63,522.42,686.36,208.710,247.912,158.722,406.7

Table II shows incidence rates for all cancers (excluding skin) by world area and sex. Two indices are used, the age standardized rate per 100,000 (standardized to the world standard population) and the cumulative rate (percent), from birth to age 65. Both of these indicators allow comparisons between populations that are not influenced by differences in their age structures. Age standardized rates in developed countries are about twice those in developing countries; the differential is less for the cumulative rate, which ignores disease rates in the 65 and over age groups. On average, worldwide, there is about a 10% chance of getting a cancer before age 65. Incidence (and mortality) rates are highest in North America, Australia/New Zealand and Western Europe, and lowest in parts of Africa. This overall risk is, of course, dependent upon the contributions of different types of cancer. For example, in West Africa, incidence of almost all cancers is low (except for cervix cancer in women and liver cancer in men). This contrasts with Southern Africa, which has, in addition, high rates of lung and oesophagus cancer, and with East Africa, with high rates of AIDS-related tumours, notably Kaposi's sarcoma.

Table II. Incidence of Cancer (All Sites Excluding Skin) by World Area
 ASR (world) per 100,000Cumulative risk % (age 0–64)
MaleFemaleMaleFemale
Eastern Africa177.7176.49.411.3
Middle Africa141.8121.67.77.9
Northern Africa124.5106.86.87.2
Southern Africa217.5153.79.48.7
Western Africa81.294.14.86.6
Caribbean187.9177.27.69.7
Central America178.5213.87.511.9
South America201.4201.89.311.2
North America357.4281.516.215.3
Eastern Asia205.3126.610.57.3
Southeastern Asia131.1120.17.07.8
South Central Asia106.6112.06.27.8
Western Asia151.1111.38.06.9
Eastern Europe290.0197.216.212.4
Northern Europe263.4235.110.913.0
Southern Europe275.4194.313.311.1
Western Europe318.7230.614.913.2
Australia/New Zealand358.6283.215.615.8
Melanesia149.8178.37.410.9
Micronesia175.5149.69.49.1
Polynesia200.7216.39.913.1
More developed countries301.0218.314.412.5
Less developed countries153.8127.98.28.0
World201.9157.810.09.2

DISCUSSION

The statistics used to assess the importance (burden) of cancer and of different types of cancer in the population either quantify the disease itself (the “need” for services) or the demand that it places upon them.24 Incidence rates provide a measure of the risk of developing specific cancers in different populations. Changes in incidence are the appropriate indicator of the impact of primary prevention strategies. Mortality rates are sometimes used as a convenient proxy measure of the risk of acquiring the disease (incidence) when comparing different groups, since they may be more generally available. However, this use assumes equal survival in the populations being compared, and this assumption may well be incorrect, for example, there are well-documented differences between countries. Mortality does provide an unambiguous measure of the outcome or impact of cancer and, used in conjunction with data on incidence, is the index of choice for the evaluation of the effects of early diagnosis or treatment. Prevalence, as the number of persons ever diagnosed with cancer (lifetime prevalence), does not have much apparent utility. The data can be derived from cancer registries that have very long-term registration of cases and complete follow-up for vital status over many years.25, 26 Population surveys are another approach, although they underestimate true prevalence.27 In the absence of complete data, an estimate can be prepared using models that incorporate longtime series of incidence and survival.28, 29 Other workers have attempted to define the proportion and timing of “cure” for different cancers, so that only patients not cured are considered prevalent.30 The data needed for such calculations are rarely available, however, and, for international comparisons, a simpler approach is needed. Partial prevalence, as estimated in GLOBOCAN, as well as approximating the numbers of patients under treatment or follow-up, does not require long time series of incidence or survival data (or a further set of assumptions required to estimate them).

Compound indicators, which use information on the duration or severity of disease, have a genuine utility in setting priorities within health-care systems. They include person-years of life lost (how many years of normal life span are lost due to deaths from cancer)31 and disability or quality-adjusted life-years lost.32, 33 The latter measures require that a numerical score is given to the years lived with a reduced quality of life between diagnosis and death (where quality = 0) or cure (quality = 1). The problem with such indicators, however, is that there is simply insufficient quantitative information on quality or disability following a cancer diagnosis in different cultures (or countries) worldwide to permit calculation of valid comparative statistics.

The GLOBOCAN estimates of incidence, mortality and (5-year) prevalence help to define priorities for cancer control program (prevention and treatment, aided by early detection, if appropriate). For countries with well-established sources of data, changes in the estimates over time indicate progress against cancer. Incidence trends can monitor the success of prevention and the success of treatment (resulting from earlier diagnosis or more effective therapies). In addition, the geographic patterns of cancer internationally serve one of the classic roles of descriptive epidemiology: observing whether the distribution of specific cancers follows the patterns expected from the distribution of known risk factors between populations or whether there are apparent anomalies that merit further investigation. GLOBOCAN 2000 incorporates the best currently available national statistics, but as information systems extend to all countries of the world and improve their coverage and accuracy, we expect that our knowledge of the world cancer burden will improve and so too will our ability to mount effective strategies against it.

Ancillary